GVHD after chemotherapy conditioning in allogeneic transplanted mice

Bone Marrow Transplantation

Volumn 42, Issue 12, 2008, Pages 807-818

  Sadeghi, B ^a   Aghdami, N ^a   Hassan, Z ^a,b   Forouzanfar, M ^a   Rozell, B ^a   Abedi Valugerdi, M ^c   Hassan, M ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW DEPRESSION; CHIMERA; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DONOR; ENGRAFTMENT; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE CELL; LIVER CELL; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; MYELOABLATIVE CONDITIONING; NONHUMAN; PRIORITY JOURNAL; SKIN CELL; SPLEEN CELL; T LYMPHOCYTE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MICE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 58149193415     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.261     Document Type: Article

References (61)

1. Thomas ED. Stem cell transplantation: Past, present and future. Stem Cells 1994; 12: 539-544.
2. Storb R. Allogeneic hematopoietic stem cell transplantation - yesterday, today, and tomorrow. Exp Hematol 2003; 31: 1-10.
3. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
4. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
5. Tabbara IA. Allogeneic bone marrow transplantation: Acute and late complications. Anticancer Res 1996; 16: 1019-1026.
6. Blazar BR, Taylor PA, Snover DC, Bluestone JA, Vallera DA. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier. J Immunol 1993; 150: 265-277.
7. Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL et al CCR2 is required for CD8-induced graft-versus-host disease. Blood 2005; 106: 3322-3330.
8. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003; 78: 181-187.
9. Deeg HJ. Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction. Int J Hematol 2001; 74: 26-32.
10. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
11. Santos GW. Preparative regimens: Chemotherapy versus chemoradiotherapy. A historical perspective. Ann N Y Acad Sci 1995; 770: 1-7.
12. Wiebe VJ, Smith BR, DeGregorio MW, Rappeport JM. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 1992; 13: 241-270.
13. Vriesendorp HM. Aims of conditioning. Exp Hematol 2003; 31: 844-854.
14. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N et al One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511-533.
15. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
16. Ferry C, Socie G. Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned? Exp Hematol 2003; 31: 1182-1186.
17. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
18. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte Jr J, Crawford JM et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996; 88: 3230-3239.
19. Perl A. Pathogenesis and spectrum of autoimmunity. Methods Mol Med 2004; 102: 1-8.
20. Lefrancois L, Lycke N. Isolation of mouse small intestinal intraepithelial lymphocytes, Peyer's patch, and lamina propria cells. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Storber W (eds). Current Protocols in Immunology, Vol. 1. John Wiley & Sons, Inc.: Hoboken, NJ, USA, 1996. Unite no 3.19 pages (3.19.1-3.19.16) (ISBN 0-471-52276-7).
21. Nilsson C, Forsman J, Hassan Z, Abedi-Valugerdi M, O'Connor C, Concha H et al. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice. Exp Hematol 2005; 33: 380-387.
22. Fontaine P, Perreault C. Diagnosis of graft-versus-host disease in mice transplanted across minor histocompatibility barriers. Transplantation 1990; 49: 1177-1179.
23. Blazar BR, Murphy WJ. Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philos Trans R Soc Lond B Biol Sci 2005; 360: 1747-1767.
24. Korngold R, Sprent J. Graft-versus-host disease in experimental allogeneic bone marrow transplantation. Proc Soc Exp Biol Med 1991; 197: 12-18.
25. Dutt S, Ermann J, Tseng D, Liu YP, George TI, Fathman CG et al. L-selectin and beta7 integrin on donor CD4T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood 2005; 106: 4009-4015.
26. Rosset MB, Tieng V, Charron D, Toubert A. Differences in MHC-class I presented minor histocompatibility antigens extracted from normal and graft-versus-host disease (GVHD) mice. Clin Exp Immunol 2003; 132: 46-52.
27. Ferrara J, Guillen FJ, Sleckman B, Burakoff SJ, Murphy GF. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: Histologic analysis and correlation to clinical disease. J Invest Dermatol 1986; 86: 371-375.
28. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
29. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C et al Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
30. Ploemacher RE, Johnson KW, Rombouts EJ, Etienne K, Westerhof GR, Baumgart J et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004; 10: 236-245.
31. Jopling C, Rosendaal M. A cautionary tale: How to delete mouse haemopoietic stem cells with busulphan. Br J Haematol 2001; 113 970-974.
32. Hassan Z, Hellstrom-Lindberg E, Alsadi S, Edgren M, Hagglund H, Hassan M. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. Bone Marrow Transplant 2002; 30: 141-147.
33. Hassan Z, Nilsson C, Hassan M. Liposomal busulphan: Bioavailability and effect on bone marrow in mice. Bone Marrow Transplant 1998; 22 913-918.
34. Panoskaltsis-Mortari A, Price A, Hermanson JR, Taras E, Lees C, Serody JS et al. In vivo imaging of graft-versus-host-disease in mice. Blood 2004; 103: 3590-3598.
35. Hamilton BL, Parkman R. Acute and chronic graft-versus-host disease induced by minor histocompatibility antigens in mice. Transplantation 1983; 36: 150-155.
36. Korngold B, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978; 148: 1687-1698.
37. Fukui J, Inaba M, Ueda Y, Miyake T, Hosaka N, Kwon AH et al. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells. Stem Cells 2007; 25: 1595-1601.
38. van Leeuwen L, Guiffre A, Atkinson K, Rainer SP, Sewell WA. A two-phase pathogenesis of graft-versus-host disease in mice. Bone Marrow Transplant 2002; 29: 151-158.
39. Heldal D, Brinch L, Evensen SA, Tjonnfjord GE, Aamodt G, Elgjo K et al. Skin biopsies for early diagnosis and prognosis of graft-versus-host disease in recipients of allogeneic stem cells from blood or bone marrow. Bone Marrow Transplant 2004; 34: 345-350.
40. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001; 29: 259-277.
41. Yoo YH, Gilliam AC, Whitaker-Menezes D, Korngold R, Murphy GF. Experimental induction and ultrastructural characterization of apoptosis in murine acute cutaneous graft-versus-host disease. Arch Dermatol Res 1997; 289: 389-398.
42. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166: 1280-1289.
43. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: Recent advances. Transl Res 2007; 150: 197-214.
44. Hofmeister CC, Quinn A, Cooke KR, Stiff P, Nickoloff B, Ferrara JL. Graft-versus-host disease of the skin: Life and death on the epidermal edge. Biol Blood Marrow Transplant 2004; 10: 366-372.
45. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
46. Dutt S, Tseng D, Ermann J, George TI, Liu YP, Davis CR et al. Naive and memory T cells induce different types of graft-versus-host disease. J Immunol 2007; 179: 6547-6554.
47. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 2000; 105: 1289-1298.
48. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183: 2645-2656.
49. Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential in.ltration of T-cell subsets. Blood 2005; 106: 1113-1122.
50. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
51. Murai M, Yoneyama H, Ezaki T, Suematsu M, Terashima Y, Harada A et al Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 2003; 4: 154-160.
52. Guy-Grand D, Vassalli P. Gut injury in mouse graft-versus-host reaction. Study of its occurrence and mechanisms. J Clin Invest 1986; 77 1584-1595.
53. Clouthier SG, Ferrara JL, Teshima T. Graft-versus-host disease in the absence of the spleen after allogeneic bone marrow transplantation. Transplantation 2002; 73: 1679-1681.
54. Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation 1987; 44: 335-339.
55. Sprent J, Schaefer M, Lo D, Korngold R. Properties of purified T cell subsets. II. In vivo responses to class I vs class II H-2 differences. J Exp Med 1986; 163: 998-1011.
56. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990; 323: 315-321.
57. Tschetter JR, Mozes E, Shearer GM. Progression from acute to chronic disease in a murine parent-into-F1 model of graft-versus-host disease. J Immunol 2000; 165: 5987-5994.
58. Piguet PF. GVHR elicited by products of class I or class II loci of the MHC: Analysis of the response of mouse T lymphocytes to products of class I and class II loci of the MHC in correlation with GVHR-induced mortality, medullary aplasia, and enteropathy. J Immunol 1985; 135: 1637-1643.
59. van Dijken PJ, Wimperis J, Crawford JM, Ferrara JL. Effect of graft-versus-host disease on hematopoiesis after bone marrow transplantation in mice. Blood 1991; 78: 2773-2779.
60. Storek J, Wells D, Dawson MA, Storer B, Maloney DG. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 2001; 98: 489-491.
61. LeBien TW. Fates of human B-cell precursors. Blood 2000; 96: 9-23.